Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company that develops RNA-based medicines to restore protein expression in severe genetic diseases. Its news flow is closely tied to the progress of its antisense oligonucleotide programs, particularly zorevunersen for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
Investors following STOK news can expect regular updates on clinical development milestones. These include announcements on the global Phase 3 EMPEROR study of zorevunersen in children and adolescents with Dravet syndrome, multi-year data from open-label extension studies, and analyses comparing treated patients with natural history data. Stoke also reports on natural history research such as the FALCON study in ADOA, which informs the design of interventional trials like the OSPREY Phase 1 study of STK-002.
Regulatory and collaboration developments are another important category of news. Stoke highlights regulatory designations for zorevunersen, including orphan drug, rare pediatric disease, and Breakthrough Therapy Designation, as well as its strategic collaboration with Biogen, under which the companies jointly advance zorevunersen for Dravet syndrome with defined regional commercialization rights.
Corporate and financial updates appear in press releases and are often paired with SEC filings. These items cover quarterly financial results, cash runway commentary, stock-based inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in major healthcare and investor conferences. Webcasts and conference calls for analysts and investors are also announced through news releases.
For anyone researching STOK, the news stream provides context on how Stoke Therapeutics is advancing its TANGO antisense platform, executing clinical trials in rare neurological and ophthalmic diseases, and managing its partnerships and capital to support ongoing development.
Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine, has announced the granting of stock options to three new employees as an inducement for their employment. The grants, effective July 15, 2024, include options to purchase a total of 122,900 shares of common stock at an exercise price of $14.58 per share, equal to the closing price on the grant date.
These options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months. The options have a 10-year term and are subject to the company's 2023 Inducement Plan and individual stock option agreements.
Stoke Therapeutics (Nasdaq: STOK), a biotechnology company, announced the grant of stock options to purchase 10,400 shares of common stock to a new employee, effective June 17, 2024. This inducement follows Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $15.60 per share, aligning with the closing price of Stoke’s stock on the grant date. The options vest over four years, with 1/4th vesting after one year and the remaining shares vesting monthly over the next 36 months. These options have a 10-year term and are governed by the 2023 Inducement Plan and the relevant stock option agreement.
Stoke Therapeutics (Nasdaq: STOK), a biotechnology firm focused on RNA-based medicines, will present at two major investor conferences in June 2024. The events include the Goldman Sachs 45th Annual Global Healthcare Conference on June 10 at 4:00 p.m. ET and the TD Cowen Genetic Medicines & RNA Summit on June 20 at 10:00 a.m. ET. Live webcasts and replays of these events will be accessible on the company's investor relations website.
Stoke Therapeutics (Nasdaq: STOK) announced the granting of stock options as a material inducement for the employment of their new Chief Financial Officer, Thomas Leggett, and four other new employees. Effective May 15, 2024, Mr. Leggett received options to purchase 396,200 shares at $14.13 per share, while the other four employees received options to purchase a combined total of 65,000 shares at the same price. Each option will vest over four years, with 1/4th vesting on the one-year anniversary and the remainder vesting monthly over the next 36 months, contingent on continued employment. The options have a 10-year term and are governed by the 2023 Inducement Plan and corresponding agreements.
Stoke Therapeutics (STOK) reported positive data supporting the potential of STK-001 as a disease-modifying medicine for Dravet syndrome. The company plans a randomized, controlled study update in late 2024. Recent financial results revealed $178.6 million in cash, with $120.3 million added from a public offering.
Stoke Therapeutics, Inc. (Nasdaq: STOK) appoints Thomas Leggett as Chief Financial Officer, replacing Stephen Tulipano. Leggett, with over 20 years of experience in biotechnology and investment banking, will lead the financial strategy and operations, overseeing the company's growth and development.
FAQ
What is the current stock price of Stoke Therapeutics (STOK)?
What is the market cap of Stoke Therapeutics (STOK)?
